Answer :
Final answer:
DOXAPRAM should not be used in newborns due to its lack of effectiveness and potential adverse effects. Other interventions such as positive pressure ventilation and supplemental oxygen are preferred for managing respiratory depression in newborns.
Explanation:
The drug DOXAPRAM should not be used in newborns due to its potential side effects and lack of effectiveness in improving respiratory function in this population. DOXAPRAM is a respiratory stimulant that is used to treat respiratory depression in adult patients. However, its use in newborns has not been shown to be beneficial and may even have adverse effects on their delicate physiological systems.
In newborns, the immature respiratory control centers are still developing, and their respiratory drive is primarily governed by the levels of carbon dioxide and oxygen in their blood. The use of DOXAPRAM can interfere with this normal respiratory control mechanism and may cause complications such as cardiovascular instability, apnea (temporary cessation of breathing), and oxygen desaturation.
